Every 424B that CDT Equity Inc. (CDT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CDT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDT filings page.
CDT Equity Inc. registers 5,348,058 shares of Common Stock for resale by selling stockholders. The registration covers 925,925 shares issuable under an amended equity line of credit with Ascent Partners Fund LLC and 4,422,133 shares issued in connection with the Sarborg Limited purchase transaction. The Company states it will not receive any proceeds from sales by the selling stockholders and the shares may be sold from time to time at market, negotiated or private prices. The prospectus notes a 1-for-25 reverse stock split effective March 26, 2026 and references an ELOC capacity of $25.0 million.
CDT amends its prospectus supplement to increase the amount of common stock that may be sold under its Sales Agreement with A.G.P./Alliance Global Partners to $76,077,218 as of April 2, 2026. This Amendment upgrades the previously stated offering capacity of $3,556,586 to the larger aggregate amount because the company’s public float exceeded $75.0 million as of March 24, 2026, allowing use of General Instruction I.B.1 of Form S-3. The prospectus notes the company is an emerging growth company and a smaller reporting company, and discloses a last reported sale price of $5.10 per share on April 1, 2026.
CDT Equity Inc. is registering 22,846,452 shares of common stock for resale by existing holders. The shares relate to stock issued for consulting services, an equity line of credit with Ascent Partners Fund, and a sale-and-purchase agreement with Corvus Capital that includes pre-funded warrants.
This is a resale registration, so CDT will not receive proceeds from investors’ purchases under this prospectus. However, a separate equity line allows CDT, at its option, to sell up to $25 million of stock to Ascent over up to 36 months, subject to price and ownership limits.
Corvus, an entity controlled by CDT’s CEO, received CDT shares and 3,685,815 pre-funded warrants as $7,000,000 consideration for acquiring subsidiary CPL and its related litigation exposure. CDT highlights substantial funding needs, an accumulated deficit of $47.0 million as of September 30, 2025, a quarterly net loss of $7.1 million, potential Nasdaq listing risk, and the chance that these resales and any future issuances may significantly dilute existing stockholders and pressure the share price.